Elsevier Journal International Immunopharmacology Celebrates 10 Years of Publication
Dedicated conference in October 2010 will mark 10th anniversary of the journal
Oxford, UK, 27 April 2010 - Elsevier, the world-leading publisher of scientific, technical and medical information products and services, is commemorating the 10th anniversary of publication of its journal International Immunopharmacology by organizing an International Immunopharmacology Conference on Regulatory Myeloid Cells from 21-24 October 2010 in Arlington VA, USA, located near Washington DC.
Since its inception in 2001 International Immunopharmacology has been a primary vehicle for the publication of peer-reviewed original research papers and review articles pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Under the guidance of the Editor in Chief, James Talmadge of the University of Nebraska Medical Center in Omaha, the journal has developed into an internationally respected, high quality platform for researchers and clinicians interested in examining how the immune system interacts with pharmacologically active agents, particularly with a view to discovering new drug targets in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders, as well as studies on cell-derived or humoral factors that modify the immune system.
In the past decade, clinical and laboratory research has focused on the role of myeloid cells in cancer, sepsis, inflammation, infections, trauma, and autoimmunity and there is now significant evidence supporting a role for myeloid cell expansion and activation in the regulation of T-cell number and function. It is highly appropriate therefore for International Immunopharmacology and Elsevier to organise a Conference on the topic of Regulatory Myeloid Cells, to bring together scientists and clinicians from the diverse fields in which myeloid cells have a critical role, to engender productive discussions, novel hypotheses and foster new collaborations, all of which are critical to the development of this exciting new field.
The Organizing Committee has developed a strong programme with excellent speakers covering many of the more exciting research areas developing in this important field. Dr. Talmadge, Editor in Chief of International Immunopharmacology, said, “The activity of myeloid regulatory cells is currently the “hottest” research area in immunology, providing an exciting focus for our first conference.”
The conference will bring together scientists and clinicians from the diverse fields in which myeloid cells have a critical role, to discuss their expansion, bio-distribution, trafficking, differentiation, regulation, and function. We expect that this conference will engender productive discussions, novel hypotheses and will foster new collaborations, all of which are critical to the development of this exciting new field.
Further information on the conference and the speaker program can be found online at the dedicated conference website: http://www.immunopharmacology.elsevier.com/.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact:
+44 1865 843181